Dual Therapy for Coronary Disease: How Safe Is It?
November 12, 2025
-
2 min
8 Key Takeaways
-
1
AQUATIC trial investigated aspirin in patients with chronic coronary syndrome.
-
2
Increased risks of cardiovascular and all-cause mortality observed in aspirin group.
-
3
Trial terminated early due to excess deaths linked to aspirin use.
-
4
Major bleeding incidence:
-
5
2% aspirin vs.
-
6
4% placebo.
-
7
Recommended re-evaluation of aspirin in high-risk patients with anticoagulation.
-
8
Conducted across 51 sites in France with 872 participants.
A recent study from the AQUATIC trial revealed that adding aspirin to oral anticoagulation therapy in patients with chronic coronary syndrome increased the risk of cardiovascular and all-cause mortality. Conducted across 51 sites in France with 872 participants who had undergone coronary stent implantation, the double-blind trial was halted early after 2.2 years due to excess deaths among those taking aspirin. Key findings included higher rates of major bleeding and serious adverse events in the aspirin group, highlighting a need to reconsider its use in such high-risk patients.
Listen Tab content
